Novocure Newsroom

Novocure Is Maintained at Overweight by Piper Sandler

Dow JonesDec 13 21:23

NovoCure Analyst Ratings

BenzingaDec 13 21:13

Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42

Futu NewsDec 13 20:31

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)

TipRanksDec 10 20:13

A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40

Futu NewsDec 3 21:01

Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential

TipRanksDec 3 00:59

Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating

MT NewswiresDec 3 00:40

Novocure Raised to Outperform From In-Line by Evercore ISI Group

Dow JonesDec 2 20:01

Evercore Upgrades Novocure(NVCR.US) to Buy Rating, Raises Target Price to $30

Futu NewsDec 2 19:31

NovoCure Analyst Ratings

BenzingaNov 22 02:01

NovoCure's Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential Risks

TipRanksNov 21 23:34

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30

Futu NewsNov 21 23:32

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)

TipRanksNov 5 20:42

NovoCure Analyst Ratings

BenzingaOct 31 17:35

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30

Futu NewsOct 30 23:31

Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28

Futu NewsOct 25 20:35

Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28

Futu NewsOct 17 18:36

Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $28

Futu NewsOct 17 03:31

A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $28 to $40

Futu NewsOct 16 21:04

Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)

TipRanksOct 16 20:10